Ensysce Biosciences (ENSCW) Operating Income (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Operating Income of -$3.7 million for Q3 2025, down 680.24% year-over-year from $644746.0 in Q3 2024, and down 113.71% quarter-over-quarter from -$1.8 million in Q2 2025.
Ensysce Biosciences (ENSCW) Operating Income (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Operating Income data on file, last reported at -$3.7 million in Q3 2025.
- Operating Income for Q3 2025 came in at -$3.7 million, down 680.24% year-over-year; the trailing twelve-month figure through Sep 2025 was -$11.0 million (down 74.91% YoY), and the FY2024 annual result was -$6.7 million, up 37.21% from the prior year.
- Operating Income fell to -$3.7 million in Q3 2025 per ENSCW's latest filing, from -$1.8 million in the prior quarter.
- Over five years, Operating Income peaked at $644746.0 in Q3 2024 and troughed at -$16.9 million in Q3 2021.
- A 5-year average of -$3.6 million and a median of -$2.6 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2021 and 2024: Operating Income tumbled 4071.91% in 2021, then jumped 123.81% in 2024.
- A 5-year view of Operating Income shows it stood at -$2.0 million in 2021, then plunged by 209.0% to -$6.2 million in 2022, then soared by 49.11% to -$3.2 million in 2023, then fell by 13.33% to -$3.6 million in 2024, then dropped by 4.6% to -$3.7 million in 2025.
- Business Quant data shows ENSCW's Operating Income at -$3.7 million in Q3 2025, -$1.8 million in Q2 2025, and -$2.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.74 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -3.58 Mn |
| Sep 30, 2024 | 644,746.00 |
| Jun 30, 2024 | -1.96 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -2.71 Mn |
| Jun 30, 2023 | -2.29 Mn |
| Mar 31, 2023 | -2.56 Mn |
| Dec 31, 2022 | -6.20 Mn |
| Sep 30, 2022 | -6.16 Mn |
| Jun 30, 2022 | -7.06 Mn |
| Mar 31, 2022 | -4.80 Mn |
| Dec 31, 2021 | -2.01 Mn |
| Sep 30, 2021 | -16.89 Mn |
| Jun 30, 2021 | -412,617.00 |
| Mar 31, 2021 | -524,273.00 |
| Dec 31, 2020 | -1.09 Mn |